Can we avoid dose escalation for intermediate-risk prostate cancer in the setting of short-course neoadjuvant androgen deprivation?
Shakespeare, Thomas, Aherne, Noel, Wilcox, SheaLanguage:
english
Journal:
OncoTargets and Therapy
DOI:
10.2147/OTT.S102327
Date:
March, 2016
File:
PDF, 306 KB
english, 2016